Bio Green Med Solution, Inc.
BGMSBio Green Med Solution, Inc. in brief
Bio Green Med Solution, Inc. is a listed company in the Biotechnology industry, based in the USA. It was founded in 1997. Its market value was $6 M on 26 October 2026, which makes it the 26,590th largest listed company in the world and the 4,364th largest in the USA on this site. In the year to December 2025 it had sales of $1 M and a net loss of $3 M. It employs about 19 people. Its largest product and service lines by sales in 2025 were Product Revenue Fire Safety (100%), Fire Safety Equipment (81%) and Safety Aparel (16%). By market, the largest shares of its 2025 sales came from Malaysia (100%). Its shares trade under the symbol BGMS (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Bio Green Med Solution, Inc.
In December 2024, Bio Green Med Solution, Inc., a Delaware corporation formerly known as Cyclacel Pharmaceuticals, Inc., announced that it was in the process of exploring and reviewing strategic alternatives on an expedited basis in order to preserve the Company’s cash, including a potential transaction with investor, David E. Lazar of Activist Investing, LLC. On January 2, 2025, the Company entered into a securities purchase agreement with Lazar, pursuant to which he agreed to purchase from the Company, 1,000,000 shares of Series C Convertible Preferred Stock and 2,100,000 shares of Series D Convertible Preferred Stock of Cyclacel at a purchase price of $1.00 per share for aggregate gross proceeds of $3.1 million, subject to the terms and conditions of the securities purchase agreement. The proceeds of the transaction were used to settle outstanding liabilities of the Company and other general corporate and operating purposes.
Bio Green Med Solution, Inc. timeline
- 1996
- 🏁· approximateFounded
- 2000
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2006
- ✎Renamed Cyclacel Pharmaceuticals, Inc.Formerly Xcyte Therapies Inc.
- 2025
- 💰Record revenue of $1 millionFY2025, the highest of the 4 years on record.
- ✎Renamed Bio Green Med Solution, Inc.Formerly Cyclacel Pharmaceuticals, Inc..
Events of Bio Green Med Solution, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,672 (Jan 2020) · #4,518 (Jan 2021) · #5,587 (Jan 2022) · #5,045 (Jul 2023) · #4,463 (Jan 2024) · #4,343 (Oct 2026) · #4,367 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 8.4×
- Price / book
- 0.9×
- Free cash flow yield
- -256.3%
- Net margin
- -400.0%
- Operating margin
- -1124.0%
- Return on equity
- -43.9%
- Liabilities / assets
- 16.4%
- Revenue growth
- +1775.0%
- R&D / revenue
- 113.3%
- Revenue per employee
- $39 K
- Profit per employee
- $-158 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1M | +1775.0% | $-8M | $-3M | -400.0% |
| Dec 2024 | $0M | -90.5% | $-12M | $-11M | -28025.0% |
| Dec 2023 | $0M | — | $-25M | $-23M | -5371.4% |
| Dec 2022 | — | — | $-28M | $-21M | — |
| Dec 2021 | — | — | $-22M | $-18M | — |
| Dec 2020 | — | — | $-11M | $-8M | — |
| Dec 2019 | — | — | $-10M | $-8M | — |
| Dec 2018 | $0M | — | $-10M | $-7M | -4860.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-5M | — | — | $-6.45 | — |
| Dec 2024 | $-8M | — | — | $-502.46 | — |
| Dec 2023 | $-16M | $0M | $-16M | $-6419.18 | — |
| Dec 2022 | $-21M | $0M | $-21M | $-27.24 | — |
| Dec 2021 | $-19M | $0M | $-19M | $-2.09 | — |
| Dec 2020 | $-8M | $0M | $-8M | $-3.42 | — |
| Dec 2019 | $-9M | $0M | $-9M | $-9.84 | — |
| Dec 2018 | $-7M | $0M | $-7M | $-0.62 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $0M (+462.5% on a year earlier), net income $-0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 4, 20268-KCurrent reportListing notice
- Oct 16, 20268-KCurrent reportOther events
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 14, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Jul 1, 20268-KCurrent reportOther events
- Jun 22, 20268-KCurrent reportShareholder vote
- Jun 10, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- Jun 4, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- May 15, 202610-QQuarterly report · period to Mar 2026
- May 14, 20268-KCurrent reportResults of operations · Regulation FD disclosure
Official filings of Bio Green Med Solution, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-8 M
- Net income
- $-3 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $8 M
- Total liabilities
- $1 M
- Total equity
- $7 M
As of December-2025
Top 11 institutional investors in Bio Green Med Solution, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Fiduciary Trust Co | 55,704 | New | 0.84% | $0 M | Nov 13, 2026 |
| 2 | Citadel Advisors LLC | 30,788 | -44,452 (-59.08%) | 0.46% | $0 M | Nov 16, 2026 |
| 3 | XTX Topco Ltd | 24,337 | New | 0.37% | $0 M | Nov 16, 2026 |
| 4 | Jane Street Group, LLC | 10,474 | -5,817 (-35.71%) | 0.16% | $0 M | Nov 12, 2026 |
| 5 | Tower Research Capital LLC (TRC) | 4,567 | -1,155 (-20.19%) | 0.07% | $0 M | Nov 16, 2026 |
| 6 | SBI Securities Co., Ltd. | 730 | +29 (+4.14%) | 0.01% | $0 M | Oct 22, 2026 |
| 7 | UBS Group AG | 44 | -4,288 (-98.98%) | 0.00% | $0 M | Nov 10, 2026 |
| 8 | Root Financial Partners, LLC | 7 | New | 0.00% | $0 M | Oct 21, 2026 |
| 9 | Barclays PLC | 4 | New | 0.00% | $0 M | Nov 6, 2026 |
| 10 | Citigroup Inc | 1 | New | 0.00% | $0 M | Nov 4, 2026 |
| 11 | Archer Investment Corp | 1 | -1 (-50.00%) | 0.00% | $0 M | Nov 5, 2026 |
Mutual funds holding Bio Green Med Solution, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 16,327 | $0 M | 0.25% | <0.01% | +828% | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of May 31, 2026. The 1 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Bio Green Med Solution, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Cu Seng KiuChief Financial Officer, Director | Grant or award | +200,000 | $1.400 | $280 K | 200,000 | Form 4 |
| filed | Doris Wong Sing EeChief Executive Officer, Director, 10% owner | Grant or award | +300,178 | $1.400 | $420 K | 1.11 M | Form 4 |
| filed | Kim Choy Yap10% owner | Sell | -28,540 | $1.700 | $49 K | 0 | Form 4 |
| filed | Yee Lung Ong10% owner | Other | +467,535 | — | — | 467,535 | Form 4 |
| filed | Khai Loon Kua10% owner | Other | +467,535 | — | — | 467,535 | Form 4 |
| filed | Kim Choy Yap10% owner | Other | +467,535 | — | — | 467,535 | Form 4 |
| filed | Yee Lung Ong10% owner | Sell | -248,814 | $1.800 | $448 K | 0 | Form 4 |
| filed | Khai Loon Kua10% owner | Sell | -242,477 | $1.800 | $436 K | 0 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Bio Green Med Solution, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-14.93 reverse split ; 1-for-20 reverse split
Trading halts
- 2026-09-14 14:28 UTC, code LUDP, resumed 14:33 UTC
- 2025-10-20 15:21 UTC, code LUDP, resumed 15:26 UTC
- 2025-10-13 13:36 UTC, code LUDP, resumed 13:41 UTC
- 2025-08-13 19:05 UTC, code LUDP, resumed 19:15 UTC
- 2025-07-18 15:38 UTC, code LUDP, resumed 15:43 UTC
Fails to deliver
- : 1,250 shares at $0.95
- : 55 shares at $1.00
- : 779 shares at $0.94
- : 2,418 shares at $0.93
- : 206 shares at $0.82
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Bio Green Med Solution, Inc. scorecard#
Passes 4 of the 12 checks that could be worked out: strongest in valuation (2 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 26, 2026.
Valuation2 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.9×Price to book 0.9× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median8.4×Price to sales 8.4× against Biotechnology's median of 8.7×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-6.45 vs -502.46Diluted EPS -6.45 in fiscal 2025 against -502.46 the year before (report's currency).
- ✓Net income higher than five years earlier-$3 M-$3 M in fiscal 2025 against -$8 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$3 MNet income -$3 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-128.5%-128.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities4.7×Current ratio 4.71 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-77.54Z-score -77.54 (distress zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Bio Green Med Solution, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0.7+1637%100% | 0.0−89.8%100% | 0.4—100% | 0—— | 0—— | 0—— | — | 0.2—100% | 0−100%— | 0.8—100% | |
| Research and development | 0.8−87.3%114% | 6.7−65.3%15477% | 19−5.5%4561% | 20+35.8%— | 15r15+214%— | 4.8+2.2%— | 4.7+7.6%— | 4.3+2.1%2885% | 4.2−55.3%— | 9.5—1124% | |
| Selling, general and administrative | — | 5.4−19.7%12540% | 6.7−9.0%1600% | 7.4−1.1%— | 7.5+27.0%— | 5.9+17.0%— | 5.0−6.5%— | 5.4+2.2%3581% | 5.3−4.7%— | 5.5—654% | |
| General and administrative | 7.7+43.1%1033% | 5.4−19.7%12540% | 6.7—1600% | — | — | — | — | — | — | — | |
| Operating expenses | 9.2−23.8%1228% | 12−53.4%28016% | 26−6.4%6160% | 28+23.5%— | 22—— | — | — | 9.7+2.2%6465% | 9.5—— | — | |
| Total costs and expenses | — | — | — | 28+20.6%— | 23+116%— | 11+9.9%— | 9.7−0.2%— | 9.7+2.2%6465% | 9.5−36.7%— | 15—1779% | |
| Operating income | −8.4—−1128% | −12—−27916% | −25—−6060% | −28—— | −22r−23—— | −11—— | −9.7—— | −9.5—−6365% | −9.5—— | −14—−1679% | |
| Interest and finance income | — | 0.0−95.5%27.9% | 0.3+26.7%63.3% | 0.2+1213%— | 0.0−61.9%— | 0.0−81.3%— | 0.2−32.3%— | 0.3+181%221% | 0.1+219%— | 0.0—4.4% | |
| Net interest income | 0.1+417%8.3% | 0.0—27.9% | — | — | — | — | — | — | — | — | |
| Other non-operating income (expense) | 5.4+54260%728% | 0.0—23.3% | −0.1−106%−23.3% | 1.7+753%— | 0.2−78.6%— | 1.0+71.8%— | 0.6−39.8%— | 0.9−10.2%615% | 1.0+173%— | 0.4—44.6% | |
| Income before tax | −3.0—−400% | −12—−27893% | −26—−6084% | −26—— | −22r−23—— | −9.7—— | −9.1—— | −8.6—−5750% | −8.5—— | −14—−1634% | |
| Income tax | 0.0—0.9% | −0.8—−1819% | −3.0—−713% | −4.7—— | −3.7r−3.8—— | −1.2—— | −1.3—— | −1.3—−891% | −1.0—— | −2.0—−235% | |
| Net income including minority interests | — | −11—−26074% | −23—−5370% | — | −18—— | — | — | — | — | — | |
| Net income attributable to shareholders | −3.0—−401% | −11—−26074% | −23—−5370% | −21—— | −18r−19—— | −8.4—— | −7.8—— | −7.3—−4859% | −7.5—— | −12—−1399% | |
| Earnings per share, basic | -6.45—— | -502.46r-2.09—— | -6,419.18r-26.75—— | -1.90—— | -2.09r-2.14—— | -3.42—— | -9.84r-0.49—— | -0.62—— | -1.95—— | -3.50—— | |
| Earnings per share, diluted | -6.45—— | -502.46r-2.09—— | -6,419.18r-26.75—— | -27.24r-1.90—— | -2.09r-2.14—— | -3.42—— | -9.84r-0.49—— | -0.62—— | -1.95—— | -3.50—— | |
| Shares, weighted average (basic) | 2.2+9692%— | 0.0r5.4−99.4%— | 3.5r0.9−68.5%— | 11+26.1%— | 8.9+146%— | 3.6—— | — | — | — | — | |
| Shares, weighted average (diluted) | 2.2+9692%— | 0.0r5.4−99.4%— | 3.5r0.9−68.5%— | 11+26.1%— | 8.9+146%— | 3.6+345%— | 0.8r16−93.3%— | 12+58.5%— | 7.6+123%— | 3.4—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 3.5+11.7%42.8% | 3.1−7.1%76.6% | 3.4−81.6%38.4% | 18−49.8%65.4% | 37+9.4%84.8% | 33+181%90.8% | 12−32.1%77.6% | 18−26.8%88.3% | 24+44.7%92.0% | 17—84.0% | |
| Short-term investments | — | — | — | 4.5+1.6%16.2% | 4.5−15.9%10.4% | 5.3−52.2%14.5% | 11−33.2%72.8% | 17−26.8%84.2% | 23+104%87.7% | 11—56.9% | |
| Receivables | 1.3—15.4% | — | — | — | — | — | — | — | — | 0.0—0.1% | |
| Inventory | 1.4—16.9% | — | — | — | — | — | — | — | — | — | |
| Other current assets | 0.1−63.3%1.3% | 0.3r0.3−12.0%7.3% | 0.3−20.0%3.9% | 0.4r0.4+439%1.5% | 0.1+19.7%0.2% | 0.1−35.9%0.2% | 0.1−56.4%0.7% | 0.2r0.2+123%1.2% | 0.1r0.1+159%0.4% | 0.0r0.0—0.2% | |
| Current assets | 6.3+70.3%76.4% | 3.7−50.6%89.7% | 7.4−69.5%84.5% | 24−40.4%87.0% | 41+15.4%94.9% | 35+153%96.4% | 14−29.2%91.6% | 20−23.8%99.8% | 26+32.4%99.9% | 20—99.8% | |
| Property, plant and equipment | 0.1+4467%1.7% | 0.0−66.7%0.1% | 0.0−71.9%0.1% | 0.0−50.0%0.1% | 0.1−39.6%0.1% | 0.1+293%0.3% | 0.0−25.0%0.2% | 0.0+24.1%0.2% | 0.0−35.6%0.1% | 0.0—0.2% | |
| Right-of-use (leased) assets | 0.0+140%0.1% | 0.0−94.6%0.1% | 0.1−34.5%1.1% | 0.1+373%0.5% | 0.0−97.6%0.1% | 1.2−2.9%3.3% | 1.3—8.3% | — | — | — | |
| Goodwill | 1.6—19.2% | — | — | — | — | — | — | — | — | — | |
| Total assets | 8.2+99.9%100% | 4.1−53.5%100% | 8.8−68.6%100% | 28r28−35.0%100% | 43r43+17.2%100% | 37+140%100% | 15−22.8%100% | 20−23.8%100% | 26+32.3%100% | 20—100% | |
| Accounts payable | 0.6−86.6%7.5% | 4.6+29.8%112% | 3.5+38.3%40.2% | 2.6+21.0%9.1% | 2.1+312%4.9% | 0.5−42.2%1.4% | 0.9−67.3%5.8% | 2.7+74.5%13.7% | 1.6−37.6%6.0% | 2.5—12.7% | |
| Current liabilities | 1.3−78.7%16.3% | 6.3−23.2%153% | 8.2+8.7%92.7% | 7.5r7.4+38.8%26.8% | 5.4r5.3+118%12.5% | 2.5+2.7%6.8% | 2.4−45.6%15.8% | 4.5+8.2%22.5% | 4.1−21.8%15.8% | 5.3—26.7% | |
| Lease liabilities (non-current) | 0.0—0.0% | 0−100%0.0% | 0.0−65.1%0.4% | 0.1+253%0.4% | 0.0−97.2%0.1% | 1.1−11.3%2.9% | 1.2—7.8% | — | — | — | |
| Total liabilities | 1.3−78.6%16.4% | 6.3−23.5%153% | 8.2+7.6%93.1% | 7.6r7.5+39.9%27.2% | 5.4r5.3+53.6%12.6% | 3.5−1.9%9.6% | 3.6−20.7%23.6% | 4.6+7.4%23.0% | 4.2−21.4%16.3% | 5.4—27.4% | |
| Retained earnings | −454—−5552% | −439—−10735% | −428—−4864% | −406r−406—−1446% | −385r−385—−891% | −366—−995% | −358—−2336% | −350—−1765% | −343—−1317% | −335—−1704% | |
| Shareholders' equity | 6.8—83.6% | −2.2−458%−53.1% | 0.6−96.2%6.9% | 16r16−57.7%56.8% | 38r37+13.3%87.4% | 33+184%90.4% | 12−23.4%76.4% | 15−29.8%77.0% | 22+52.5%83.7% | 14—72.6% | |
| Total equity | — | −2.2−458%−53.1% | 0.6—6.9% | — | — | — | — | — | — | — | |
| Total liabilities and equity | 8.2+99.9%100% | 4.1−53.5%100% | 8.8−68.6%100% | 28r28−35.0%100% | 43r43+17.2%100% | 37+140%100% | 15−22.8%100% | 20−23.8%100% | 26+32.3%100% | 20—100% | |
| Shares outstanding | 5.4+14530%— | 0.0r8.9+737%— | 0.0r1.1−99.3%— | 0.6r13−93.7%— | 10.0+60.0%— | 6.2+626%— | 0.9r17−93.1%— | 12+4.2%— | 12+182%— | 4.3—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | — | — | 0.00.0%— | 0.0−31.0%— | 0.0r29−99.9%19.3% | 32r0.0+31900%— | 0.1—11.9% | |
| Share-based compensation | 2.3+294%312% | 0.6−59.8%1377% | 1.5−2.2%351% | 1.5+30.2%— | 1.2+169%— | 0.4−7.7%— | 0.5+40.8%— | 0.3+24.4%221% | 0.3−66.0%— | 0.8—92.8% | |
| Cash from operating activities | −4.8—−639% | −8.0—−18581% | −16—−3836% | −21—— | −19—— | −7.9—— | −9.4—— | −6.7—−4467% | −7.5—— | −10—−1196% | |
| Capital expenditure | — | — | −0.0—−1.4% | −0.0—— | −0.0—— | −0.1—— | −0.0—— | −0.0—−26.0% | −0.0—— | −0.0—−0.4% | |
| Cash from investing activities | — | — | −0.0—−1.4% | −0.0—— | −0.0—— | −0.1−443%— | 0.0—— | −0.0—−26.0% | −0.0−244%— | 0.0—1.1% | |
| Shares issued | — | — | — | — | 4.0−86.5%— | 30+634%— | 4.0+543%— | 0.6−95.7%420% | 15+117%— | 6.8—806% | |
| Cash from financing activities | 5.3−32.7%705% | 7.8+822%18191% | 0.8−71.7%202% | 3.0−86.2%— | 22−26.3%— | 30+667%— | 3.8+797%— | 0.4−97.1%286% | 15+124%— | 6.6—782% | |
| Exchange-rate effect on cash | — | — | — | — | −0.0−136%— | 0.0—— | −0.0—— | −0.1—−63.3% | — | — | |
| Change in cash | 0.4—49.3% | −0.2—−560% | −15—−3564% | −18−678%— | 3.2−85.3%— | 22—— | −5.6—— | −6.4−187%−4271% | 7.4—— | −3.9—−465% | |
| Report | 10-K | 10-K | 10-K/A | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 2.2—100% | 0.5+460%100% | 0.3—100% | 0.7—100% | 0.7r0.7*—100% | 0.1+710%100% | — | — | 0*−100%— | 0.0—100% | 0.0—100% | 0.0—100% | 0.0*—100% | |
| Research and development | — | — | — | — | — | 0.0−99.5%6.2% | 0.1−96.6%— | 0.8−70.7%— | 0.9*−75.0%— | 1.0—9500% | 2.0—50575% | 2.8—9662% | 3.5*—11348% | |
| Selling, general and administrative | — | — | — | — | — | — | — | — | 0.9*−49.4%— | 1.2—12370% | 1.6—40625% | 1.6—5455% | 1.9*—6042% | |
| General and administrative | 2.8−62.6%126% | 0.6−36.8%140% | 0.5−60.2%148% | 0.4−90.8%52.4% | 1.3*+31.9%188% | 1.0−18.8%1240% | 1.2−23.1%— | 4.2+166%— | 0.9*—— | 1.2—12370% | 1.6—40625% | 1.6—5455% | — | |
| Operating expenses | 5.4−35.5%245% | 1.0−8.8%215% | 0.8−39.6%224% | 1.0−75.7%138% | 2.6r1.7*+44.6%397% | 1.1r1.1−51.2%1319% | 1.2r1.3−65.8%— | 4.2r5.0−3.9%— | 1.8*−66.1%— | 2.2—21870% | 3.6—91200% | 4.4—15117% | 5.4*—17390% | |
| Operating income | −3.2—−144% | −0.5—−115% | −0.4—−124% | −0.2—−33.1% | −2.0r−1.1*—−297% | −1.0r−1.0—−1219% | −1.2r−1.3—— | −4.2r−5.0—— | −1.8*—— | −2.2—−21770% | −3.6—−91100% | −4.4—−15017% | −5.4*—−17290% | |
| Interest and finance income | — | — | — | — | — | — | — | — | — | — | — | 0.0—6.9% | 0.0*—74.2% | |
| Net interest income | 0.1+128%4.9% | 0.0+389%9.7% | 0.0+350%2.7% | 0.0+50.0%1.2% | 0.0*+50.0%6.8% | 0.0+12.5%11.1% | 0.0—— | 0.0+200%— | 0.0*—— | 0.0—80.0% | −0.0—−700% | 0.0—6.9% | — | |
| Other non-operating income (expense) | 5.6—255% | 0.1+1750%16.3% | 0.0+2100%6.5% | 0.1+888%10.6% | 5.4r0.5*—814% | 0.0−60.0%4.9% | 0.0—— | 0.0r5.0−85.5%— | −0.0*—— | 0.0—100% | −0.0—−625% | 0.1—190% | −0.3*—−1074% | |
| Income before tax | 2.4—111% | −0.4—−98.2% | −0.4—−118% | −0.2—−22.5% | 3.4r−0.6*—517% | −1.0r−1.0—−1214% | −1.2r−1.3—— | −4.2r−0.1—— | −1.9*—— | −2.2—−21670% | −3.7—−91725% | −4.3—−14828% | −5.7*—−18365% | |
| Income tax | 0.0—2.1% | 0.0—0.7% | 0.0+350%2.7% | 0.0—4.0% | 0.0*−99.6%0.8% | 0*—0.0% | 0.0—— | — | 1.2*—— | −0.2—−2100% | −0.4—−10300% | −1.4—−4669% | −0.4*—−1361% | |
| Net income including minority interests | — | — | — | — | — | — | — | −0.1—— | −3.1*—— | −2.0*—−19570% | −3.3*—−81425% | −2.9—−10159% | −5.3*—−17003% | |
| Net income attributable to shareholders | −1.7—−75.6% | −0.4—−98.9% | −0.4—−121% | −0.2—−26.5% | −0.6*—−91.7% | −1.0—−1220% | −1.3—— | −0.1—— | −3.1*—— | −2.0—−19570% | −3.3—−81425% | −2.9—−10159% | −5.3*—−17003% | |
| Earnings per share, basic | — | -0.07—— | — | — | — | -1.31—— | -0.98—— | 0.00—— | — | -43.80—— | -172.18—— | -2.27—— | — | |
| Earnings per share, diluted | — | -0.07—— | — | — | — | -1.31—— | -0.98—— | 0.00—— | — | -43.80—— | -172.18—— | -2.27—— | — | |
| Shares, weighted average (basic) | 6.6+246%— | 6.6+246%— | 5.6+311%— | 5.5+1395%— | — | 1.9+4180%— | 1.4—— | 0.4—— | — | 0.0—— | — | — | — | |
| Shares, weighted average (diluted) | 6.6+246%— | 6.6+246%— | 5.6+311%— | 5.5+1395%— | — | 1.9+4180%— | 1.4—— | 0.4—— | — | 0.0—— | — | — | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 3.5—46.2% | 3.5−10.0%46.2% | 3.8−11.3%48.3% | 3.3−3.2%44.1% | 3.5+11.7%42.8% | 3.8+28.7%47.0% | 4.3−28.7%97.1% | 3.5+23.3%92.4% | 3.1−7.1%76.6% | 3.0—55.4% | 6.0—73.3% | 2.8—45.4% | 3.4—38.4% | |
| Receivables | 1.0—13.0% | 1.0+34.3%13.0% | 1.1—13.7% | 1.2—15.7% | 1.3—15.4% | 0.7—8.9% | — | — | — | — | — | — | — | |
| Inventory | 1.0—13.3% | 1.0−27.6%13.3% | 1.0—12.4% | 0.9—12.5% | 1.4—16.9% | 1.4—16.8% | — | — | — | — | — | — | — | |
| Other current assets | 0.2—2.1% | 0.2−65.7%2.1% | 0.1+129%1.7% | 0.1−23.7%2.0% | 0.1−63.3%1.3% | 0.5+48.9%5.6% | 0.1−80.7%1.3% | 0.2−46.8%5.2% | 0.3r0.3−12.0%7.3% | 0.3—5.7% | 0.3—3.7% | 0.4—5.9% | 0.3—3.9% | |
| Current assets | 5.6—74.6% | 5.6−13.5%74.6% | 6.0+36.2%76.0% | 5.6+51.4%74.3% | 6.3+70.3%76.4% | 6.4+31.2%79.0% | 4.4−43.1%99.6% | 3.7−23.2%99.5% | 3.7−50.6%89.7% | 4.9—91.3% | 7.7—94.1% | 4.8—78.4% | 7.4—84.5% | |
| Property, plant and equipment | 0.1—1.8% | 0.1+3.9%1.8% | 0.1+13500%1.7% | 0.1+13700%1.8% | 0.1+4467%1.7% | 0.1+3125%1.6% | 0.0−80.0%0.0% | 0.0−85.7%0.0% | 0.0−66.7%0.1% | 0.0—0.1% | 0.0—0.1% | 0.0—0.1% | 0.0—0.1% | |
| Right-of-use (leased) assets | 0.0—0.1% | 0.0−66.7%0.1% | 0.0−58.8%0.1% | 0.0−47.4%0.1% | 0.0+140%0.1% | 0.0−70.6%0.2% | 0.0−73.8%0.4% | 0.0−75.9%0.5% | 0.0−94.6%0.1% | 0.1—0.9% | 0.1—0.8% | 0.1—1.3% | 0.1—1.1% | |
| Goodwill | 1.6—21.0% | 1.60.0%21.0% | 1.6—20.0% | 1.6—20.8% | 1.6—19.2% | 1.6—19.2% | — | — | — | — | — | — | — | |
| Total assets | 7.5—100% | 7.5−8.3%100% | 7.9+78.5%100% | 7.6+103%100% | 8.2+99.9%100% | 8.2+51.6%100% | 4.4−46.3%100% | 3.7−39.4%100% | 4.1−53.5%100% | 5.4—100% | 8.2—100% | 6.2—100% | 8.8—100% | |
| Accounts payable | 0.2—2.4% | 0.2−61.3%2.4% | 0.2−14.5%2.4% | 0.3+125%3.4% | 0.6−86.6%7.5% | 0.5−88.7%5.7% | 0.2−95.3%5.0% | 0.1−97.8%3.1% | 4.6+29.8%112% | 4.1—76.7% | 4.7—57.9% | 5.2—84.3% | 3.5—40.2% | |
| Current liabilities | 0.8—10.9% | 0.8−18.7%10.9% | 0.7−8.9%8.8% | 0.8+20.1%10.5% | 1.3−78.7%16.3% | 1.0−84.2%12.3% | 0.8−89.4%17.3% | 0.7−92.1%17.8% | 6.3−23.2%153% | 6.4—118% | 7.2—87.7% | 8.4—135% | 8.2—92.7% | |
| Lease liabilities (non-current) | — | — | — | — | 0.0—0.0% | 0.0—0.1% | 0.0+100%0.2% | 0.0−57.1%0.2% | 0−100%0.0% | 0—0.0% | 0.0—0.1% | 0.0—0.3% | 0.0—0.4% | |
| Total liabilities | 0.8—10.9% | 0.8−23.1%10.9% | 0.7−9.9%8.8% | 0.8+19.6%10.6% | 1.3−78.6%16.4% | 1.1−83.3%13.0% | 0.8−89.3%17.5% | 0.7−92.0%18.0% | 6.3−23.5%153% | 6.4—118% | 7.2—87.8% | 8.4—136% | 8.2—93.1% | |
| Retained earnings | −455—−6091% | −455—−6091% | −455—−5793% | −455—−6010% | −454—−5552% | −444—−5446% | −442—−10038% | −440—−11796% | −439—−10735% | −436—−8111% | −434—−5305% | −431—−6995% | −428—−4864% | |
| Shareholders' equity | 6.7—89.1% | 6.7−6.1%89.1% | 7.2+97.2%91.2% | 6.8+121%89.4% | 6.8—83.6% | 7.1—87.0% | 3.6+263%82.5% | 3.1—82.0% | −2.2−458%−53.1% | −1.0—−18.0% | 1.0—12.2% | −2.2—−35.8% | 0.6—6.9% | |
| Total equity | — | — | — | — | — | — | 3.6+263%82.5% | 3.1—82.0% | −2.2−458%−53.1% | — | 1.0—12.2% | −2.2—−35.8% | 0.6—6.9% | |
| Total liabilities and equity | 7.5—100% | 7.5−8.3%100% | 7.9+78.5%100% | 7.6+103%100% | 8.2+99.9%100% | 8.2+51.6%100% | 4.4−46.3%100% | 3.7−39.4%100% | 4.1−53.5%100% | 5.4—100% | 8.2—100% | 6.2—100% | 8.8—100% | |
| Shares outstanding | 6.6—— | 6.6+89.4%— | 6.6+318%— | 5.5−97.3%— | 5.4+14530%— | 3.5+62.5%— | 1.6−12.3%— | 207+15628%— | 0.0r8.9+737%— | 2.2—— | 1.8—— | 1.3—— | 0.0r1.1—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 0.7−62.9%29.9% | 0*−100%0.0% | 0.0−85.7%0.3% | 0.0−99.9%0.1% | 0.7*+604%98.3% | 0.0−94.4%7.4% | 0.0−96.3%— | 1.7+721%— | 0.1*−71.1%— | 0.1—1070% | 0.2—4725% | 0.2—700% | 0.3*—1039% | |
| Cash from operating activities | −1.0—−43.2% | −0.3*—−63.2% | −0.4*—−105% | −0.3—−37.4% | −0.0*—−5.0% | −0.4*—−536% | −1.1*—— | −3.2—— | −1.4*—— | −3.1*—−30670% | −3.1*—−77100% | −0.5—−1666% | −3.9*—−12613% | |
| Capital expenditure | — | 0*—0.0% | 0*—0.0% | −0.0—−0.1% | — | — | — | — | — | 0*—0.0% | — | — | 0*—0.0% | |
| Cash from investing activities | — | 0*—0.0% | 0*—0.0% | −0.0—−0.1% | — | — | — | — | — | 0*—0.0% | — | — | 0*—0.0% | |
| Cash from financing activities | 0.6−91.6%27.2% | −0.0*—−4.4% | 0.8*−58.9%230% | 0.1−97.1%14.1% | −0.3*−116%−38.9% | −0.0*—−3.7% | 1.9*−70.1%— | 3.6—— | 1.6*+61.5%— | −0.0*—−10.0% | 6.3*—157225% | −0.1—−272% | 1.0*—3223% | |
| Change in cash | −0.4−145%−17.5% | −0.3*—−74.0% | 0.5*−45.3%134% | −0.2−153%−22.3% | −0.3*−315%−50.0% | −0.4*—−540% | 0.8*−74.2%— | 0.3—— | 0.2*—— | −3.0*—−30180% | 3.2*—80050% | −0.6—−2000% | −2.6*—−8277% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K/A | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Bio Green Med Solution, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product Revenue Fire Safety$1 M100%—
- Fire Safety Equipment$1 M81%—
- Safety Aparel$0 M16%—
- Project Supply and Installation$0 M2.7%—
- Maintenance and Servicing$0 M0.8%—
Business segments
- Single Reportable$1 M100%+1775%
Countries and regions
- 🇲🇾 Malaysia$1 M100%—
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Bio Green Med Solution, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office | — |
| 🇲🇾 Malaysia | $1 M100% |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Bio Green Med Solution, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Chief executive | $847 K | $847 K | $785 K | $0 |
| 2024Chief executive | $585 K | $548 K | $364 K | $4 |
| 2023Chief executive | $661 K | $66 K | $833 K | $27 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Bio Green Med Solution, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Auditor changed 1 · Acquisition or sale completed 2 · Directors and officers 1 · Material agreement 7 · Unregistered share sale 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Acquisition or sale completedMaterial agreement | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Acquisition or sale completedShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2025 | $1 M | Private placement after listing | Under $2 million | 4 | equity | SEC |
| Nov 2024 | $2 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| May 2024 | $8 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Dec 2020 | $7 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Mar 2012 | $3 M | Private placement after listing | $2 to $10 million | 7 | equity, options | SEC |
| Oct 2010 | $15 M | No. 1 | $10 to $50 million | 20 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2005 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| 14% of workforce | Restructuring planSEC 8-K | “As a result of this more limited clinical development plan, the Company reduced its workforce by approximately 14%, from 83 to 71 employees, on May 17, 2005.” | Filing | |
| 24% of workforce | Restructuring planSEC 8-K | “Item 2.05 Costs Associated with Exit or Disposal Activities As a result of the Registrant’s plan to limit clinical development primarily to the planned Phase II/III trial in CLL an…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Bio Green Med Solution, Inc. compares in Biotechnology
- Market cap$6 M · higher than 7% of 726
- Revenue$1 M · higher than 23% of 647
- Net margin-400.0% · higher than 16% of 408
- Revenue growth1775.0% · higher than 99% of 438
- Price / sales8.4× · lower than 48% of 339
- Price / book0.9× · lower than 81% of 534
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Bio Green Med Solution, Inc.🇺🇸 | $6 M | — | -400.0% | +1775.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 26, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Bio Green Med Solution, Inc.? Verify and update this profile — free
Show Bio Green Med Solution, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.